Multicenter phase III trial studying trospium chloride in patients with overactive bladder

Delbert Rudy, Kevin Cline, Richard Harris, Kenneth Goldberg, Roger Dmochowski

Research output: Contribution to journalArticlepeer-review

86 Scopus citations


Objectives. To study the efficacy and safety of trospium chloride in treating overactive bladder. Trospium chloride is an anticholinergic agent with predominantly peripheral nonselective antimuscarinic activity and thus has potential therapeutic value in treating patients with overactive bladder. Methods. Patients with overactive bladder were randomized on a 1:1 basis to either placebo or trospium chloride 20 mg twice daily in this 12-week, multicenter, parallel, double-blind, placebo-controlled study. The primary endpoint was the change in the average number of toilet voids per 24 hours. The secondary efficacy variables were changes in the average void urgency severity, volume per toilet void, urge frequency, number of daily urge urinary incontinence episodes, and daytime sleepiness. Results. A total of 658 patients were randomized at 52 sites. Trospium chloride significantly decreased the average number of daily toilet voids, average urgency severity, urge frequency, and urge urinary incontinence episodes and increased the average volume per void at weeks 1, 4, and 12. All effects occurred by the end of week 1 and all improved and were sustained throughout the 12-week study. Adverse events included dry mouth and constipation. Conclusions. Trospium chloride had significant and sustained effectiveness beginning at the end of week 1 and continuing through 12 weeks of treatment. Trospium chloride was also safe and generally well tolerated.

Original languageEnglish (US)
Pages (from-to)275-280
Number of pages6
Issue number2
StatePublished - Feb 2006

ASJC Scopus subject areas

  • Urology


Dive into the research topics of 'Multicenter phase III trial studying trospium chloride in patients with overactive bladder'. Together they form a unique fingerprint.

Cite this